AI and glucose monitors may predict surgery risks for rare tumors

NCT ID NCT07516275

Not yet recruiting Knowledge-focused Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will enroll 200 patients scheduled for surgery to remove rare adrenal tumors called pheochromocytomas or paragangliomas (PPGL). Before surgery, researchers will use a model to predict the risk of severe blood pressure swings during the operation. During surgery, a real-time early warning tool will be tested to see if it can predict blood pressure changes 60 seconds ahead. The study also tests continuous glucose monitors and an AI agent for preoperative assessment, but does not change standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better prediction and real-time warning of dangerous blood pressure changes during surgery, making the operation safer for patients.
What could go wrong: This is an early observational study, not a treatment trial. The models may not be accurate enough to change practice, and results may not apply to other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMODYNAMIC INSTABILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Intraoperative Complications paraganglioma pheochromocytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMODYNAMIC INSTABILITY INTRAOPERATIVE COMPLICATIONS PARAGANGLIOMA PHEOCHROMOCYTOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.